Company news

Aroa Biosurgery Ltd news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

US CMS Confirms Symphony Outpatient Reimbursement Rate

November 8, 2026

Aroa Biosurgery H1 FY27 Results & Investor Event

November 3, 2026

AROA Appoints Mark Dunwoodie as CFO

November 2, 2026

Change in substantial shareholding for ARX

October 18, 2026

Molnlycke to Co-promote Endoform In the US

October 15, 2026

Notification of cessation of securities - ARX

October 12, 2026

Investor Presentation - Symphony RCT

October 11, 2026

Invite to Investor Webinar on Symphony RCT

October 6, 2026

Investor Presentation - MASTRR Interim Analysis

October 6, 2026

Change in substantial holding

October 6, 2026

Symphony™ Randomized Controlled Trial Demonstrates Significantly Improved Healing of Diabetic Foot Ulcers

October 5, 2026

Symphony Significantly Improves DFU Healing

October 4, 2026

Invite to Investor Webinar on MASTRR Interim Analysis

September 28, 2026

Peer-reviewed 411-patient study reports low infection rates with Myriad™ in complex soft tissue reconstruction

September 6, 2026

Myriad MASTRR Study Reports Low Infection Rates

September 3, 2026

Change of Director's Interest Notice - BW

August 27, 2026

Notification regarding unquoted securities - ARX

August 27, 2026

Final Director's Interest Notice - JD

August 20, 2026

Results of Annual General Meeting

August 19, 2026

CEO Presentation - AGM

August 18, 2026

Chairman's Address - AGM

August 18, 2026

Notification of cessation of securities - ARX

August 11, 2026

Notification regarding unquoted securities - ARX

August 11, 2026

Change in substantial shareholding for ARX

August 6, 2026

Notification regarding unquoted securities - ARX

July 27, 2026

Commercial Leadership Appointments

July 27, 2026

FY26 Full Year Results Presentation

May 25, 2026

FY26 Appendix 4E and Full Year Results

May 25, 2026

ARX FY26 Preliminary Results

April 29, 2026

Symphony Randomised Control Trial Complete

March 29, 2026

AROA Business Update Presentation

February 2, 2026

AROA Business Update

February 2, 2026

Study demonstrates effectiveness and economic value of Myriad™ in trauma and acute care surgery.

January 20, 2026

Aroa Biosurgery H1 FY26 Results

November 24, 2025

Appendix 4D and Half Year Report

November 24, 2025

September 2025 Quarterly Report and Appendix 4C

October 15, 2025

First clinical evidence published on AROA's ENIVO™ system for surgical dead space management.

August 26, 2025

June 2025 Quarterly Report and Appendix 4C

July 28, 2025

FY25 Full Year Results Presentation

May 28, 2025

FY25 Appendix 4E and Full Year Results

May 28, 2025

AROA hits evidence milestone with real-world study validating the efficacy of Endoform in treating challenging venous leg ulcers.

May 1, 2025

March 2025 Quarterly Report and Appendix 4C

April 28, 2025

December 2024 Quarterly Report and Appendix 4C

January 28, 2025

Aroa Half Year Results Presentation

November 25, 2024

Aroa Biosurgery Half Yearly Results H1 FY25

November 25, 2024

September 2024 Quarterly Report and Appendix 4C

October 21, 2024

June 2024 Quarterly Report and Appendix 4C

July 23, 2024

FY24 Full Year Results Presentation

May 20, 2024

FY24 Appendix 4E and Full Year Results

May 20, 2024

March 2024 Quarterly Report and Appendix 4C

April 29, 2024

Older news releases →

Decks

The 5 newest of 39 decks. Every deck is listed under its year.